

Rev 1: September 2018

FSN Ref: FSN-2022-004 FSCA Ref: FSN-2022-004

Date: 16 March 2022

Urgent Field Safety Notice (FSN)

Thermo Scientific™ Remel™ Culti-Loops™ Candida albicans ATCC™ 10231™ PK/5

For Attention of*: Lab Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*

E.mail : mbd.vigilance@thermofisher.com
Telephone: +44(0) 1256 841144

Fax: +44(0) 1256 479525



Rev 1: September 2018 FSN Ref: FSN-2022-004

FSCA Ref: FSN-2022-004

Urgent Field Safety Notice (FSN)

Thermo Scientific™ Remel™ Culti-Loops™ Candida albicans ATCC™ 10231™ PK/5

	1. Information on Affected Devices*					
1.	1. Device Type(s)*					
	IVD					
1.	Commercial name(s)					
Remel™ Culti-Loops™ Candida albicans ATCC™ 10231™ PK/5						
1.	Unique Device Identifier(s) (UDI-DI)					
	00848838038075					
1.	Primary clinical purpose of device(s)*					
	This product is a ready to use, disposable bacteriological loop containing stabilized					
	viable microorganisms and is recommended for use in the performance testing of					
	culture media, stains, diagnostic kits and reagents, for the maintenance of stock					
	cultures and in the evaluation of bacteriological procedures.					
1.	5. Device Model/Catalogue/part number(s)*					
	R4601503					
1.	6. Software version					
	N/A					
1.	7. Affected serial or lot number range					
	294388					
1.	8. Associated devices					
	N/A					

	2. Reason for Field Safety Corrective Action (FSCA)*				
Description of the product problem*					
	An internal technical investigation has confirmed that Remel™ Culti-Loops™ Candida				
albicans ATCC™ 10231™ PK/5 R4601503 Lot 294388 may exhibit lower than e or no growth of <i>C. albicans</i> ATCC 10231.					
					2.
Lower than expected or no growth of C. albicans.					
2. 3. Probability of problem arising					
	Low to medium				
2. 4. Predicted risk to patient/users					
	There should be no immediate or long-term health consequences from use of this product. The <i>C. albicans</i> culture is a quality control strain. It should have little or no				
	effect on the ability of clinical specimens to grow such a fungus on standard primary				
	fungal isolation media. The clinical risk should be considered negligible.				
2.	5. Further information to help characterise the problem				
	N/A				
2.	6. Background on Issue				
	An internal investigation has found that R4601503 lot 294388 is not performing as				
	expected.				
2.	7. Other information relevant to FSCA				
	Lot. 294388 with the expiry of 11-Nov-2022				



Rev 1: September 2018 FSN Ref: FSN-2022-004

FSCA Ref: FSN-2022-004

	3. Type of Action to mitigate the Risk*						
3.	1.	. Action To Be Taken by the User*					
		☑ Identify Device ☐ Quarantine Device ☐ Return Device ☒ Destroy Device					
		☐ On-site device modification	/inspection				
		☐ Follow patient management recommendations					
		☐ Take note of amendment/reinforcement of Instructions For Use (IFU)					
		□ Other □ None					
3.	2.	By when should the action be completed?	Immediately				
3.	3.	3. Particular considerations for: IVD					
		Is follow-up of patients or review of patients' previous results recommended? No Provide further details of patient-level follow-up if required or a justification why none is					
3.	4.	required Is customer Reply Required? * Yes					
J.		yes, form attached specifying deadline for return)					
3.	5.						
		☐ Software upgrade ☐	On-site device modification/inspectiful or labelling change None	ection			
3	6.	By when should the action be completed?	As soon as possible				
3.	7.	Is the FSN required to be collay user?	·	No			
3	8.		ovided additional information su professional user information le				
		N/A					



Rev 1: September 2018 FSN Ref: FSN-2022-004

FSCA Ref: FSN-2022-004

	4. General Information*			
4.	1. FSN Type*	New		
4.	For updated FSN, reference number and date of previous FSN	N/A		
4.	3. For Updated FSN, key new information as follows:			
	N/A			
4.	4. Further advice or information already expected in follow-up FSN? *	Not planned yet		
4	If follow-up FSN expected, what is the further advice expected to relate to: N/A			
4	Anticipated timescale for follow- up FSN	N/A		
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)			
	a. Company Name	Remel Inc.		
	b. Address	12076 Santa Fe Trail Drive Lenexa KS 66215		
	c. Website address	www.thermofisher.com		
4.	The Competent (Regulatory) Authority of your country has been informed about this communication to customers. *			
4.	9. List of attachments/appendices:	Customer Response Form		
4.	10. Name	xxx		
	Signature			

Transmission of this Field Safety Notice This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate) Please transfer this notice to other organisations on which this action has an impact. (As appropriate) Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action. Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.*



Rev 1: September 2018 FSN Ref: FSN-2022-004

FSCA Ref: FSN-2022-004

Customer Reply Form

1. Field Safety Notice (FSN) information							
FSN Reference number*			2022-004				
FSN Date*		16 March 2022					
Product/ Device name*		TI	nermo Scie	ntific™ F	Remel™ Cu	ılti-Loops™ Candida	
		al	bicans ATC	CC™ 1023	31™ PK/5	-	
	ct Code(s)	R	4601503				
Batch/	/Serial Number (s)	29	94388				
2. Cı	ustomer Details						
Accou	int Number						
Organ	isation Name*						
Organ	isation Address*						
Depar	tment/Unit						
Shippi	ing address if different to above						
Conta	ct Name*						
Title o	r Function						
	none number*						
Email*	k						
3. Cı	ustomer action undertaken on bel	าล	If of Health	care Org	anisation		
	I confirm receipt of the Field Safety	/					
ш	Notice and that I read and						
	understood its content.						
	I performed all actions requested						
ш	by the FSN.						
	The information and required						
	actions have been brought to the						
	attention of all relevant users and						
	executed. I have returned affected devices -		Qty:	Lot/Corio	I Number:	Date Returned	
	enter number of devices returned		Qty.	Louisena	i Nullibel.	(DD/MM/YY)	
	and date complete or N/A						
	and date complete of WA		Comments:				
	I have destroyed affected devices		Qty:	Lot/Spria	I Number:	Date Returned	
	enter number destroyed and date	_	Gty.	Lowocha	ritarriber.	(DD/MM/YY)	
	complete.	_	Qty	Credit □	Replaceme		
	complete.		Comments:				
	No affected devices are available						
	for return/ destruction						
	Other Action (Define):						
	I do not have any affected devices						
Ш							
	I have a query please contact me						
	(e.g. need for replacement of the						
	product).						
Print Name*							
Signature*							
Date*							



The world leader in serving science

Rev 1: September 2018 FSN Ref: FSN-2022-004

FSCA Ref: FSN-2022-004

4. Return acknowledgement to sender		
Email	MBD.vigilance@thermofisher.com	
Telephone Number & Fax	Tel: +44(0) 1256 841144	
·	Fax :+44(0) 1256 479525	
Postal Address		
Deadline for returning the reply form*	13 April 2022	

Mandatory fields are marked with *

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.